anti-CD133-immunotoxin conjugates (PCI Biotech)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug Nameanti-CD133-immunotoxin conjugates (PCI Biotech)
Drug Alias Namemonoclonal antibody-immunotoxin conjugates (PCI Biotech)
ClassificationBiologics > Protein drugs > ToxinBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Monoclonal antibody conjugateBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody conjugate
Mechanisms of ActionCD133 inhibitors
TargetsCD133
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryNorway
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesPCI Biotech Holding ASA
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesPCI Biotech Holding ASA
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A